Literature DB >> 27851970

The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.

Amit Mandoli1, Abhishek A Singh1, Koen H M Prange1, Esther Tijchon1, Marjolein Oerlemans1, Rene Dirks1, Menno Ter Huurne1, Albertus T J Wierenga2, Eva M Janssen-Megens1, Kim Berentsen1, Nilofar Sharifi1, Bowon Kim1, Filomena Matarese1, Luan N Nguyen1, Nina C Hubner1, Nagesha A Rao1, Emile van den Akker3, Lucia Altucci4, Edo Vellenga5, Hendrik G Stunnenberg1, Joost H A Martens6.   

Abstract

The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal hematopoietic differentiation. Here, we have investigated its effects on the transcriptome and epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes with high levels of histone acetylation but also at distal elements characterized by low acetylation levels and binding of the hematopoietic transcription factors LYL1 and LMO2. In contrast, ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. While expression of AML1-ETO in myeloid differentiated induced pluripotent stem cells (iPSCs) induces leukemic characteristics, overexpression increases cell death. We find that expression of wild-type transcription factors RUNX1 and ERG in AML is required to prevent this oncogene overexpression. Together our results show that the interplay of the epigenome and transcription factors prevents apoptosis in t(8;21) AML cells.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AML1-ETO; RUNX1; acute myeloid leukemia; apoptosis; epigenome; iPSC

Mesh:

Substances:

Year:  2016        PMID: 27851970     DOI: 10.1016/j.celrep.2016.08.082

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  25 in total

1.  Histone deacetylase 3 preferentially binds and collaborates with the transcription factor RUNX1 to repress AML1-ETO-dependent transcription in t(8;21) AML.

Authors:  Chun Guo; Jian Li; Nickolas Steinauer; Madeline Wong; Brent Wu; Alexandria Dickson; Markus Kalkum; Jinsong Zhang
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

2.  Defined Human Leukemic CD34+ Liquid Cultures to Study HDAC/Transcriptional Repressor Complexes.

Authors:  Roland Windisch; Sophie Kreissig; Christian Wichmann
Journal:  Methods Mol Biol       Date:  2023

Review 3.  C/EBPα deregulation as a paradigm for leukemogenesis.

Authors:  J A Pulikkan; D G Tenen; G Behre
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

4.  RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.

Authors:  Mylène Gerritsen; Guoqiang Yi; Esther Tijchon; Jorren Kuster; Jan Jacob Schuringa; Joost H A Martens; Edo Vellenga
Journal:  Blood Adv       Date:  2019-02-12

5.  Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism.

Authors:  Xin Zhang; Can Hu; Yu-Pei Yuan; Peng Song; Chun-Yan Kong; Hai-Ming Wu; Si-Chi Xu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Cell Biol Toxicol       Date:  2021-01-20       Impact factor: 6.691

6.  AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.

Authors:  Abhishek A Singh; Amit Mandoli; Koen H M Prange; Marko Laakso; Joost H A Martens
Journal:  Oncotarget       Date:  2017-02-21

7.  RUNX1 cooperates with FLT3-ITD to induce leukemia.

Authors:  Kira Behrens; Katrin Maul; Nilgün Tekin; Neele Kriebitzsch; Daniela Indenbirken; Vladimir Prassolov; Ursula Müller; Hubert Serve; Jörg Cammenga; Carol Stocking
Journal:  J Exp Med       Date:  2017-02-17       Impact factor: 14.307

8.  Combined HAT/EZH2 modulation leads to cancer-selective cell death.

Authors:  Francesca Petraglia; Abhishek A Singh; Vincenzo Carafa; Angela Nebbioso; Mariarosaria Conte; Lucia Scisciola; Sergio Valente; Alfonso Baldi; Amit Mandoli; Valeria Belsito Petrizzi; Concetta Ingenito; Sandro De Falco; Valeria Cicatiello; Ivana Apicella; Eva M Janssen-Megens; Bowon Kim; Guoqiang Yi; Colin Logie; Simon Heath; Menotti Ruvo; Albertus T J Wierenga; Paul Flicek; Marie Laure Yaspo; Veronique Della Valle; Olivier Bernard; Stefano Tomassi; Ettore Novellino; Alessandra Feoli; Gianluca Sbardella; Ivo Gut; Edo Vellenga; Hendrik G Stunnenberg; Antonello Mai; Joost H A Martens; Lucia Altucci
Journal:  Oncotarget       Date:  2018-05-22

9.  Multi-omics profiling reveals a distinctive epigenome signature for high-risk acute promyelocytic leukemia.

Authors:  Abhishek A Singh; Francesca Petraglia; Angela Nebbioso; Guoqiang Yi; Mariarosaria Conte; Sergio Valente; Amit Mandoli; Lucia Scisciola; Rik Lindeboom; Hinri Kerstens; Eva M Janssen-Megens; Farzin Pourfarzad; Ehsan Habibi; Kim Berentsen; Bowon Kim; Colin Logie; Simon Heath; Albertus T J Wierenga; Laura Clarke; Paul Flicek; Joop H Jansen; Taco Kuijpers; Marie Laure Yaspo; Veronique Della Valle; Olivier Bernard; Ivo Gut; Edo Vellenga; Hendrik G Stunnenberg; Antonello Mai; Lucia Altucci; Joost H A Martens
Journal:  Oncotarget       Date:  2018-05-22

Review 10.  Cancer epigenetics: Moving forward.

Authors:  Angela Nebbioso; Francesco Paolo Tambaro; Carmela Dell'Aversana; Lucia Altucci
Journal:  PLoS Genet       Date:  2018-06-07       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.